OptionsHouse

Options Trading News

October 2, 2013  Wed 8:11 AM CT

CELG: SEE CHART GET CHAIN FIND STRATEGIES
Celgene and Merck are crosstown rivals. One's always innovating, putting money to work in a variety of biotechs, buying when the time is right. It's always going for the blockbuster, trying to press, press, press.

The other is trying to cut its way to success by firing, trimming, and hoping to eke out money as its new products fail to ignite or just fail. It's unoriginal and staid--just trying to pay that dividend.

The first is obviously Celgene, and the second is Merck, which managed to pop its stock with an announcement that is laying off a bunch of people. It's a second reduction in force for this obviously bloated company.

TheStreet.com logoBut the first used to be Merck. It used to be the ultimate in original thinking and new products. Not anymore. Even its acquisition of the gigantic Schering-Plough in 2009 seems to have gotten it nothing significant that I can see. I had hoped that at least the company would follow in the footsteps of Pfizer and spin off animal health, but even that is apparently too radical.

Either way, I think that Merck's a sell, not a buy. The market wants growth and new drugs. If it wants yield, it can get it from Con Ed. Disappointing, again.

Disclosures:
Cramer's charitable trust has no positions in the stocks mentioned.
Share this article with your friends


OptionsHouse

Premium Services

Upcoming Webinar:

How to Defend Your Portfolio and Profit in a Market Selloff

http://bit.ly/1OSMWU6

Jon Najarian and Sandy Chaikin of Chaikin Analytics demonstrate how to play defense when the market is selling off. And, how to turn misery into money, whether investing in stocks or trading options.

Education & Strategy

The sweet spot

When using the Stock Replacement Strategy, we must remember that in reality, we are doing a STOCK trade. We are just using options. We are replacing the stock position with an option position (long calls).

View more education articles »